Yung Shin Pharmaceutical, a subsidiary of Yung Shin Group, has announced the launch of a highly effective drug for the treatment of hepatitis virus infections in the United States, following its introduction in Taiwan, Japan, and Canada. This move aims to maximize the benefits of a single product. In recent years, Yung Shin has implemented a vertical integration strategy from active pharmaceutical ingredients (APIs) to formulations, revealing that, in addition to selling formulated products, it continues to receive inquiries from international pharmaceutical companies regarding procurement of APIs.
This new generic drug is intended for first-line treatment of chronic hepatitis and boasts high pharmacological activity with excellent therapeutic effects, alongside superior cost-effectiveness and production efficiency. It has become an important new star in the global healthcare market. The global market value for treating hepatitis virus infections with this drug is approximately $3.6 billion, expected to grow to $5.8 billion by 2030, with an annual compound growth rate of 6.8% from 2024 to 2030.
Yung Shin stated that, besides its launch in the U.S., the drug is already available in Taiwan, Japan, and Canada, as it strives to maximize the benefits of a single product while continuing to implement its vertical integration strategy from APIs to formulations. As uncertainties in the global pharmaceutical supply chain have intensified, Yung Shin Pharmaceutical has successfully consolidated its leading position in the generic drug sector, owing to its robust development and production capabilities in both APIs and formulations. In addition to selling antiviral formulations, it continues to receive inquiries from international pharmaceutical companies seeking to procure Yung Shin’s APIs.
The global spread of the COVID-19 pandemic has posed unprecedented challenges to the pharmaceutical industry's supply chain. The supply of APIs has faced varying degrees of restriction, leading to shortages of some essential medications. However, for Yung Shin Pharmaceutical, this crisis has accelerated the advancement of its vertical integration strategy. With the recent opportunities presented by the U.S. Biosecurity Act, Yung Shin Pharmaceutical, through its vertical integration R&D model, is able to rapidly produce and deliver products in response to actual market demands, thanks to its possession of both API and formulation manufacturing facilities.
Yung Shin emphasized that the successful market launch of its antiviral drug exemplifies the efficacy of its vertical integration strategy. By autonomously producing from APIs to formulations, Yung Shin has significantly shortened product launch cycles while maintaining high-quality standards. This rapid response capability not only enhances Yung Shin's competitiveness in the generic drug market but also allows it to stand out amid the global pharmaceutical supply chain crisis.
Chi-Li Lee, Chairman of Yung Shin Pharmaceutical, stated, "We have always upheld our corporate mission to provide patients with high-quality and economical treatment options. Through our vertical integration strategy, we have not only improved production efficiency but also further consolidated our market competitiveness. At this critical juncture of transformation and challenges in the global pharmaceutical industry, we will continue to focus on technological innovation and quality enhancement, providing the highest quality medications to meet global healthcare needs. In the future, Yung Shin Pharmaceutical will deepen its globalization efforts, upholding our corporate responsibility for continuous quality improvement and committed to delivering high-quality and economical products."
Resource (mandarin): 永信高效治肝炎病毒感染藥在美上市，翻開垂直整合策略新篇章
